Tetra Bio-Pharma Inc.

As of August 31, 2022, Tetra Bio-Pharma Inc. carries a market capitalization of 19.60M, placing it among publicly traded companies globally. Its enterprise value stands at 20.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of August 31, 2022, Tetra Bio-Pharma Inc. has 423.36M shares outstanding.

These figures are as of August 31, 2022.

As of August 31, 2022, Tetra Bio-Pharma Inc. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -28.09, indicating conservative leverage, while an interest coverage ratio of -37.20 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended August 31, 2022. Return on assets (ROA) is negative at -195.06, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 33.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended August 31, 2022, Tetra Bio-Pharma Inc. generated - - in revenue and converted that into -29.72M in net income, yielding earnings per share of -0.07. EBITDA reached -9.95M, while operating income came in at -10.03M.

As of August 31, 2022, Tetra Bio-Pharma Inc. holds 368,072.58 in cash and equivalents against 1.26M in total debt, resulting in a net debt position of 896,409.94. Total book value stands at -4.50M, with working capital of -5.09M providing operational flexibility.

Tetra Bio-Pharma Inc. produced -6.23M in operating cash flow over the twelve months ended August 31, 2022. After subtracting -23,423.40 in capital expenditures, free cash flow totaled -6.26M - equivalent to -0.02 per share.

These figures cover the twelve months ended August 31, 2022. Free cash flow yield is negative at -32.70: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.03, meaning Tetra Bio-Pharma Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Tetra Bio-Pharma Inc.'s most recent stock split took place on June 23, 2014 with a 2:1 split ratio.

As of August 31, 2022, Tetra Bio-Pharma Inc. has an Altman Z-Score of -78.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.